Cosentyx receives expanded approvals in EU for use in childhood arthritic conditions
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Many kids who have heart transplants live a normal, healthy life once they recover from surgery.
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
Covaxin was earlier approved for children 12-18 years of age
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
Govt announces vaccination programme for kids and those above 60 years of age
Subscribe To Our Newsletter & Stay Updated